<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04613492</url>
  </required_header>
  <id_info>
    <org_study_id>D7880C00001</org_study_id>
    <nct_id>NCT04613492</nct_id>
  </id_info>
  <brief_title>A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors</brief_title>
  <official_title>An Open-label, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MEDI9253, a Recombinant Newcastle Disease Virus Encoding Interleukin-12, in Combination With Durvalumab in Participants With Select Advanced/Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study D7880C00001 is a first-in-human (FIH), Phase 1, open-label, multicenter, dose&#xD;
      escalation and dose expansion study to evaluate the safety, tolerability, PK,&#xD;
      pharmacodynamics, and preliminary efficacy of MEDI9253 in combination with durvalumab in&#xD;
      adult participants with select advanced/metastatic solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to approximately 192 participants may be assigned to study intervention in the study&#xD;
      across approximately 30 sites globally.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2020</start_date>
  <completion_date type="Anticipated">November 7, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 7, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Dose Limiting Toxicities (DLTs) of the MEDI9253 during the dose escalation phase</measure>
    <time_frame>Single dose cohorts: From Day 1 through 14 days Multiple dose cohorts: From Day 1 through 28 days</time_frame>
    <description>DLTs must be treatment related and documented as Adverse Events (AEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing adverse events (AEs) /serious adverse events (SAEs)</measure>
    <time_frame>Informed consent through 90 days post last dose of study drug, estimated to be 6 months</time_frame>
    <description>AEs graded by NCI CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing adverse events (AEs) leading to discontinuation</measure>
    <time_frame>Informed consent through 90-Post last dose, estimated to be 6 months</time_frame>
    <description>AEs graded per NCI CTCAE v5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>From Day 1 through 90 days after the last dose of study drug, estimated to be 6 months</time_frame>
    <description>ORR is defined as the proportion of participants with confirmed complete response (CR) or partial response (PR). The endpoint of ORR according to RECIST v1.1, will be assessed by evaluation of the responses post baseline until progression or the start of subsequent anti-cancer therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response ( DoR)</measure>
    <time_frame>From Day 1 through 90 days after the last dose of study drug, estimated to be 6 months</time_frame>
    <description>DoR is defined as duration from first documentation of confirmed objective response (OR) to the first documented progressive disease (PD) or death. Tumor assessments will be based on RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>From Day 1 through 90 days after the last dose of study drug, estimated to be 6 months</time_frame>
    <description>TTR is defined as the time from the first dose of treatment until first documentation of subsequently confirmed OR. Tumor assessments will be based on RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Disease Control Rate (DCR)</measure>
    <time_frame>From Day 1 through 90 days after the last dose of study drug, estimated to be 6 months</time_frame>
    <description>DCR is defined as the proportion of participants with confirmed CR or PR, or stable disease (SD). Tumor assessments will be based on RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From Day 1 through 90 days after the last dose of study drug, estimated to be 6 months</time_frame>
    <description>PFS is defined as the time from first dose of treatment until first documentation of PD or death. Tumor assessments will be based on RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From Day 1 through study completion, estimated to be 1 year</time_frame>
    <description>OS is defined as the time from first dose of treatment until documentation of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with detectable viral genome copies in blood</measure>
    <time_frame>From Day 1 through 90 days</time_frame>
    <description>Presence of Viremia. Viral genome copies in blood collected over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who have immune changes in tumor microenvironment (TME) on MEDI9253 treatment</measure>
    <time_frame>From Day 1 through 90 days</time_frame>
    <description>Determine if MEDI9253 alters the TME. CD8 T cell infiltration and/or PD-L1 expression in tumors pre- and post-dosing by immunohistochemistry (IHC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with neutralizing antibodies to MEDI9253</measure>
    <time_frame>From Day 1 through 90 days after the last dose of study drug, estimated to be 6 months</time_frame>
    <description>Immunogenicity of MEDI9253. Markers of antiviral immune response (anti-MEDI9253 neutralizing antibodies)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-12 plasma concentrations</measure>
    <time_frame>From Day 1 through 90 days</time_frame>
    <description>IL-12 plasma concentrations collected over time</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Single dose MEDI9253, sequential Durvalumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Various dose level cohorts for single dose MEDI9253 with sequential Durvalumab dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose MEDI9253, sequential Durvalumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Various dose level cohorts for multiple dose MEDI9253 with sequential Durvalumab dosing;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose MEDI9253, concurrent Durvalumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Various dose level cohorts for multiple dose MEDI9253 with concurrent Durvalumab dosing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI9253</intervention_name>
    <description>Participants will receive either Single dose MEDI9253 or Multiple Dose MEDI9253; sequentially or concurrent with Durvalumab</description>
    <arm_group_label>Multiple dose MEDI9253, concurrent Durvalumab</arm_group_label>
    <arm_group_label>Multiple dose MEDI9253, sequential Durvalumab</arm_group_label>
    <arm_group_label>Single dose MEDI9253, sequential Durvalumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Durvalumab treatment will be started sequentially or concurrently with MEDI9253</description>
    <arm_group_label>Multiple dose MEDI9253, concurrent Durvalumab</arm_group_label>
    <arm_group_label>Multiple dose MEDI9253, sequential Durvalumab</arm_group_label>
    <arm_group_label>Single dose MEDI9253, sequential Durvalumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant must be at least 18 years old at signing of informed consent.&#xD;
&#xD;
          2. Body weight &gt; 35 kg at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1 Primary central nervous system (CNS) disease is excluded, as well as untreated or&#xD;
        uncontrolled metastatic CNS involvement, leptomeningeal disease, or cord compression.&#xD;
&#xD;
        NOTE: CNS disease that has been treated and stable/controlled for at least 3 months is&#xD;
        permitted. Participants with CNS disease controlled via systemic steroids are not&#xD;
        permitted.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>101 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.&#xD;
All request will be evaluated as per the AZ disclosure commitment:&#xD;
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.</ipd_description>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

